Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib

Kaelyn C Cummins; Matthew P Cheng; David W Kubiak; Matthew S Davids; Francisco M Marty; Nicolas C Issa

doi:10.1080/10428194.2018.1485913

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib

Leuk Lymphoma. 2019 Feb;60(2):527-530. doi: 10.1080/10428194.2018.1485913. Epub 2018 Jul 24.

Authors

Kaelyn C Cummins^{1

2}, Matthew P Cheng^{1

2

3}, David W Kubiak^{2

3}, Matthew S Davids^{2

3}, Francisco M Marty^{1

2

3}, Nicolas C Issa^{1

2

3}

Affiliations

¹ a Division of Infectious Diseases, Department of Medicine , Brigham and Women's Hospital , Boston , MA , USA.
² b Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.
³ c Harvard Medical School , Boston , MA , USA.

PMID: 30037292
DOI: 10.1080/10428194.2018.1485913

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Antifungal Agents / administration & dosage
Antifungal Agents / therapeutic use*
Humans
Invasive Fungal Infections / drug therapy*
Invasive Fungal Infections / etiology
Nitriles / administration & dosage
Nitriles / therapeutic use*
Piperidines
Pyrazoles / adverse effects
Pyrazoles / therapeutic use
Pyridines / administration & dosage
Pyridines / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use
Treatment Outcome
Triazoles / administration & dosage
Triazoles / therapeutic use*

Substances

Antifungal Agents
Nitriles
Piperidines
Pyrazoles
Pyridines
Pyrimidines
Triazoles
ibrutinib
isavuconazole
Adenine